James L. Bullington - Concepedia

Author

James L. Bullington

Johnson & Johnson (United States)

Also Known As

J. L. BULLINGTON, James Bullington, James L. Bullington

Publications

369

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)

About

James L. Bullington is an author at Johnson & Johnson (United States) specializing in pharmacology, drug discovery, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	114
2	Natural Sciences	3	3	83
3	Engineering	2	2	34
4	Biochemistry	2	2	67
5	Biomolecular Engineering	1	1	16

James L. Bullington

Publications

311

Citations

H-Index

Page 1

	Year	Citations
Regioselective Preparation of 2-Substituted 3,4-Diaryl Pyrroles: A Concise Total Synthesis of Ningalin B James L. Bullington, Russell R. Wolff, Paul Jackson The Journal of Organic Chemistry	2002	107
Synthesis of tetrahydroindeno[1,2-b]indol-10-ones and their rearrangement to [2]benzopyrano[4,3-b]indol-5-ones James L. Bullington, John H. Dodd The Journal of Organic Chemistry Derivative (Chemistry)Molecular SciencesDonut IconAltmetric Attention ScoreOrganic Chemistry	1993	56
In Vivo Characterization of a Dual Adenosine A<sub>2A</sub>/A<sub>1</sub> Receptor Antagonist in Animal Models of Parkinson’s Disease Brian C. Shook, Stefanie Rassnick, Melville C. Osborne, Journal of Medicinal Chemistry Dual Adenosine AReceptor AntagonistPharmacotherapyExperimental PharmacologyMedicinal Chemistry	2010	54
Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists Brian C. Shook, Stefanie Rassnick, D.W.R. Hall, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicineMethylene AminePharmacological AgentPharmacotherapy	2010	24
Stereoselectivity in the rhodium(II) acetate catalysed cyclopropanations of 2-diazo-1-indanone with styrenes William E. Bauta, John H. Dodd, James L. Bullington, Tetrahedron Letters Chemical EngineeringEngineeringHeterocyclicCatalysed CyclopropanationsAlkene Metathesis	2000	18
Synthesis of spiro[2<i>H</i>‐indole‐2,1′‐1<i>H</i>‐isoindole]‐3,3′‐diones, spiro[1<i>H</i>‐isobenzofuran‐1,2′‐2<i>H</i>‐indole]‐3,3′‐diones and spiro[benzofuran‐2,1′‐isobenzofuran]‐3,3′‐diones <i>via</i> transannular reactions of eight membered ring intermediates James L. Bullington, John H. Dodd Journal of Heterocyclic Chemistry Dibenzoxocintrione 18Diversity Oriented SynthesisDerivativesDerivatives 4–6Engineering	1998	16
The development of novel and selective p56lck tyrosine kinase inhibitors James L. Bullington, Julie C. Cameron, Janet E. Davis, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesReceptor Tyrosine Kinase	1998	13
Optimization of arylindenopyrimidines as potent adenosine A2A/A1 antagonists Brian C. Shook, Stefanie Rassnick, Devraj Chakravarty, Bioorganic & Medicinal Chemistry Letters MedicinePharmacological AgentPharmacotherapyPharmacologyDrug Discovery	2010	12
Inhibitors of unactivated p38 MAP kinase James L. Bullington, Dennis Argentieri, Kristin Averill, Bioorganic & Medicinal Chemistry Letters MedicineReceptor Tyrosine KinaseAnti-cancer AgentPharmacologyCell Biology	2006	11

Page 1